Navigation Links
DuPont Provides Technology for Washington Hospital Center's Emergency Department

DuPont Products Help Address Infection Control

WASHINGTON, Jan. 10 /PRNewswire-FirstCall/ -- To help address infection control during everyday hospital operations and minimize risks during times of health crisis, DuPont (NYSE: DD) today announced that one of its healthcare products, DuPont(TM) Corian(R) solid surface, has been selected by the Washington Hospital Center for its emergency department. The product recently was incorporated into a children's ward at the Roswell Park Cancer Institute in Buffalo, N.Y.

Washington Hospital Center is using the technology as part of its vision to build ER One, which will be an all-risks-ready emergency care facility, created to provide emergency medical care during acts of terrorism and emerging illness and built to function fully as a hospital emergency department during daily operations. The current phase of the project, entitled "Bridge to ER One," will test these new innovations and technologies.

"Our DuPont innovations are designed to provide solutions that protect lives," said Thomas F. Schuler, vice president and general manager -- DuPont Building Innovations. "Corian(R) is one of our products that uniquely meets both the stringent safety specifications of the healthcare industry as well as the aesthetic demands of healthcare designers."

The 2006 Guidelines for Design and Construction of Hospital and Healthcare Facilities has defined the 18 preferred characteristics of the ideal healthcare surface to help facilitate improved infection control. Corian(R) meets all 18 of these characteristics, including being nonporous, seamless, durable and not supporting microbial growth when cleaned properly.

"Corian(R) was selected for the Bridge to ER One because it is a seamless, easy-to-clean surface material ideally suited for healthcare environments," said Dr. Mark Smith, chairman of Emergency Medicine at Washington Hospital Center. "There is solid evidence that contaminated surfaces contribute to the spread of infections. Eliminating grout lines and crevices through the use of Corian(R) remove a potential source of microbial contamination from the patient care unit."

DuPont(TM) Corian(R) donated a total of 193 sheets and 17 sinks made of the solid surface material to this phase of the ER One project. Corian(R) was utilized for selected areas of the emergency department, including patient room wall-cladding, nurses' stations surfacing, lobby chair rails, bathroom shower stalls and integrated sinks/vanities.

In conjunction with the Centers for Health Design, Washington Hospital Center will conduct evidence-based research over a two-year period, allowing staffers to test and adjust key elements for the full ER One, which is expected to open in six to 10 years.

Washington Hospital Center is a not-for-profit 926-bed acute care teaching and research hospital based in Northwest Washington. It is the largest private medical center in the nation's capital and among the 25 largest hospitals in the Mid-Atlantic region. The Hospital Center consistently ranks among the nation's top hospitals in the research and treatment of cardiovascular and kidney disease and provides cutting-edge therapies to treat cancer, stroke and acute neurological injury and disease. Washington Hospital Center also is home to MedSTAR Trauma and Transport and is the region's adult burn facility.

DuPont(TM) Corian(R) is a nonporous, high-performing, easy-to-maintain solid surface material that, when properly used or cleaned, does not support the growth of mold or mildew. Non-toxic and non-allergenic to humans, Corian(R) has received NSF/ANSI 51 Certification for food contact and Class 1 (A) fire rating. The American Institute of Architects (AIA) Guidelines for Design and Construction of Hospital and Healthcare Facilities recommends using solid surfacing to help facilitate improved infection control.

Additional DuPont products used in healthcare facilities include:

-- DuPont(TM) Zodiaq(R) quartz surface, to provide an extremely strong,

nonporous material for desks, tables and many other applications;

-- DuPont(TM) Tyvek(R) brand protective material, for sterile medical

packaging, devices and gowns;

-- DuPont(TM) RelyOn(TM) solutions, antiseptics to disinfect, clean and

deodorize a wide range of surfaces;

-- DuPont(TM) Sontara(R), Softesse(R) and Suprel(R) medical fabrics, to

protect and provide comfort for medical personnel and patient gowns,

drapes and wipes;

-- DuPont(TM) Softesse(R) for bandages and other wound care needs;

-- DuPont(TM) Tychem(R) protective garments for emergency room first

responders, and;

-- DuPont(TM) SentryGlas(R) Plus interlayers and SentryGlas(R)

Expressions(TM) decorative interlayers, to provide safety glass that

protects people and buildings and provides high-quality imagery and


DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

The DuPont Oval, DuPont(TM), The miracles of science(TM), and Corian(R), Zodiaq(R), Tyvek(R), RelyOn(R), Sontara(R), Softesse(R), Suprel(R), Tychem(R), SentryGlas(R) Plus and SentryGlas(R) Expressions(TM) are registered trademarks or trademarks of DuPont or its affiliates.

For more information on DuPont products and services to the medical and healthcare industries, visit:

Photo: Due to length of URL, please cut and paste into browser. pon tNew&Entity=PRAsset&AttachmentType=F&EntityID=108829&AttachmentID=551bf643- b691-4386-8c51-d21302973994&NewWindow=true

Caption: DuPont(TM) Corian(R) is a nonporous, non-toxic and easy-to-clean solid surface material that, when properly used or cleaned, does not support the growth of mold or mildew.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
3. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
4. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
7. Replidyne Provides Strategic Update
8. BioCryst Provides Forodesine HCl Update
9. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
Post Your Comments:
(Date:12/1/2015)... , December 1, 2015 ... new market research report "Nucleic Acid Labeling Market by ... Nick Translation, Random Primer, In Vitro Transcription, Reverse Transcription, ... published by MarketsandMarkets, The global market is expected to ... Million in 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... , December 1, 2015 Russia ... clinical trials. 70% of new drugs registered in Europe ... Russia . --> Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
Breaking Medicine Technology:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
Breaking Medicine News(10 mins):